» Articles » PMID: 24121625

The Majority of Patients with Long-duration Type 1 Diabetes Are Insulin Microsecretors and Have Functioning Beta Cells

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2013 Oct 15
PMID 24121625
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: Classically, type 1 diabetes is thought to proceed to absolute insulin deficiency. Recently developed ultrasensitive assays capable of detecting C-peptide under 5 pmol/l now allow very low levels of C-peptide to be detected in patients with long-standing type 1 diabetes. It is not known whether this low-level endogenous insulin secretion responds to physiological stimuli. We aimed to assess how commonly low-level detectable C-peptide occurs in long-duration type 1 diabetes and whether it responds to a meal stimulus.

Methods: We performed a mixed-meal tolerance test in 74 volunteers with long-duration (>5 years) type 1 diabetes, i.e. with age at diagnosis 16 (9-23) years (median [interquartile range]) and diabetes duration of 30 (19-41) years. We assessed fasting and stimulated serum C-peptide levels using an electrochemiluminescence assay (detection limit 3.3 pmol/l), and also the urinary C-peptide:creatinine ratio (UCPCR).

Results: Post-stimulation serum C-peptide was detectable at very low levels (>3.3 pmol/l) in 54 of 74 (73%) patients. In all patients with detectable serum C-peptide, C-peptide either increased (n = 43, 80%) or stayed the same (n = 11) in response to a meal, with no indication of levels falling (p < 0.0001). With increasing disease duration, absolute C-peptide levels fell although the numbers with detectable C-peptide remained high (68%, i.e. 25 of 37 patients with >30 years duration). Similar results were obtained for UCPCR.

Conclusions/interpretation: Most patients with long-duration type 1 diabetes continue to secrete very low levels of endogenous insulin, which increase after meals. This is consistent with the presence of a small number of still functional beta cells and implies that beta cells are either escaping immune attack or undergoing regeneration.

Citing Articles

Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.

Infante M, Silvestri F, Padilla N, Pacifici F, Pastore D, Pinheiro M J Clin Med. 2025; 14(4).

PMID: 40004833 PMC: 11856673. DOI: 10.3390/jcm14041303.


Retinal Vascular Density and Thickness in Long-Term Type 1 Diabetes Without Visible Vascular Signs of Retinopathy.

Sopena-Pinilla M, Arias-Alvarez M, Lopez-Galvez M, Orduna-Hospital E, Fernandez-Espinosa G, Boned-Murillo A J Clin Med. 2025; 14(4).

PMID: 40004613 PMC: 11856492. DOI: 10.3390/jcm14041082.


Detection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes.

Krivova Y, Proshchina A, Otlyga D, Kharlamova A, Saveliev S Life (Basel). 2025; 15(1).

PMID: 39860066 PMC: 11766825. DOI: 10.3390/life15010125.


Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers.

Collins J, Farnsworth N Diabetologia. 2025; .

PMID: 39847085 DOI: 10.1007/s00125-024-06356-5.


DOC2b enrichment mitigates proinflammatory cytokine-induced CXCL10 expression by attenuating IKKβ and STAT-1 signaling in human islets.

Bhowmick D, Ahn M, Bhattacharya S, Aslamy A, Thurmond D Metabolism. 2025; 164:156132.

PMID: 39805534 PMC: 11798586. DOI: 10.1016/j.metabol.2025.156132.


References
1.
Wiedmeyer H, Polonsky K, Myers G, Little R, Greenbaum C, Goldstein D . International comparison of C-peptide measurements. Clin Chem. 2007; 53(4):784-7. DOI: 10.1373/clinchem.2006.081570. View

2.
Besser R, Shields B, Casas R, Hattersley A, Ludvigsson J . Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care. 2012; 36(2):195-201. PMC: 3554273. DOI: 10.2337/dc12-0836. View

3.
Palmer J, Fleming G, Greenbaum C, Herold K, Jansa L, Kolb H . C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2003; 53(1):250-64. DOI: 10.2337/diabetes.53.1.250. View

4.
Wang L, Lovejoy N, Faustman D . Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care. 2012; 35(3):465-70. PMC: 3322715. DOI: 10.2337/dc11-1236. View

5.
Steffes M, Sibley S, Jackson M, Thomas W . Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003; 26(3):832-6. DOI: 10.2337/diacare.26.3.832. View